Nattawat Klomjit, MD, reflects on key takeaways from ASN 2024, particularly regarding IgA nephropathy and C3 glomerulopathy. For IgA nephropathy, recent guidelines emphasize more aggressive treatment even at lower proteinuria levels, with new drugs like sibeprenlimab targeting specific pathways involved in the disease’s progression.
Complement inhibitors, such as ravulizumab and iptacopan, were also discussed for their promising impact on reducing kidney inflammation and proteinuria. In treating C3 glomerulopathy, Dr Klomjit noted the potential of investigational drugs like pegcetacoplan and iptacopan to improve both proteinuria and GFR, bringing hope for future advancements in treating these rare glomerular diseases.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASN 2024: Applying New Data to Patients With Glomerular Diseases - Medscape - Nov 15, 2024.
Comments